IL94602A - פוליפפטידים ומקבילי פוליפפטיד - Google Patents

פוליפפטידים ומקבילי פוליפפטיד

Info

Publication number
IL94602A
IL94602A IL9460290A IL9460290A IL94602A IL 94602 A IL94602 A IL 94602A IL 9460290 A IL9460290 A IL 9460290A IL 9460290 A IL9460290 A IL 9460290A IL 94602 A IL94602 A IL 94602A
Authority
IL
Israel
Prior art keywords
pro
lys
val
gly
polypeptide
Prior art date
Application number
IL9460290A
Other languages
English (en)
Other versions
IL94602A0 (en
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898913349A external-priority patent/GB8913349D0/en
Priority claimed from GB898913346A external-priority patent/GB8913346D0/en
Priority claimed from GB898921613A external-priority patent/GB8921613D0/en
Priority claimed from GB898924717A external-priority patent/GB8924717D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of IL94602A0 publication Critical patent/IL94602A0/xx
Publication of IL94602A publication Critical patent/IL94602A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL9460290A 1989-06-09 1990-06-03 פוליפפטידים ומקבילי פוליפפטיד IL94602A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898913349A GB8913349D0 (en) 1989-06-09 1989-06-09 Polypeptides
GB898913346A GB8913346D0 (en) 1989-06-09 1989-06-09 Polypeptide analogues
GB898921613A GB8921613D0 (en) 1989-09-25 1989-09-25 Polypeptides-1st update
GB898924717A GB8924717D0 (en) 1989-11-02 1989-11-02 Polypeptides

Publications (2)

Publication Number Publication Date
IL94602A0 IL94602A0 (en) 1991-04-15
IL94602A true IL94602A (he) 1996-06-18

Family

ID=27450350

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9460290A IL94602A (he) 1989-06-09 1990-06-03 פוליפפטידים ומקבילי פוליפפטיד

Country Status (16)

Country Link
US (4) US5464822A (he)
EP (1) EP0402068B1 (he)
JP (1) JP2989853B2 (he)
AT (1) ATE131493T1 (he)
AU (1) AU636148B2 (he)
CA (1) CA2018592C (he)
DE (1) DE69024104T2 (he)
DK (1) DK0402068T3 (he)
ES (1) ES2080800T3 (he)
FI (1) FI106471B (he)
GR (1) GR3018401T3 (he)
IE (1) IE70520B1 (he)
IL (1) IL94602A (he)
NO (1) NO177716C (he)
NZ (1) NZ233974A (he)
PT (1) PT94326B (he)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
DK0458537T3 (da) * 1990-05-24 1999-10-18 Zeneca Ltd Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
DK0458536T3 (da) * 1990-05-24 1998-10-19 Zeneca Ltd Terapeutisk middel til behandling og forebyggelse af åndedrætsbesværsyndrom hos voksne
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5835061A (en) 1995-06-06 1998-11-10 Wayport, Inc. Method and apparatus for geographic-based communications service
US8606851B2 (en) 1995-06-06 2013-12-10 Wayport, Inc. Method and apparatus for geographic-based communications service
EP0834556A1 (en) * 1996-09-25 1998-04-08 Academisch Ziekenhuis Leiden Methods for culturing cells
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2001241913A1 (en) * 2000-03-01 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for wound treatment
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US20030119073A1 (en) * 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
WO2003064605A2 (en) 2002-01-28 2003-08-07 Ambion, Inc. Crude biological derivatives competent for nucleic acid detection
IL164795A0 (en) * 2002-04-25 2005-12-18 Scripps Research Inst Treatment and prevention of pulmonary conditions
FR2849375B1 (fr) * 2002-12-30 2006-10-20 Jean Noel Thorel Compositions cosmetiques, par exemple pour traiter le vieillissement cutane photo-induit
CA2524626A1 (en) * 2003-05-07 2004-11-18 Vib Vzw The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells
WO2006122404A1 (en) * 2005-05-16 2006-11-23 Her Majesty The Queen In Right As Represented By The Minister Of Health Trappin-2 (elafin) inhibits hiv
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
US8211637B2 (en) * 2008-12-19 2012-07-03 Life Technologies Corporation Proteinase K inhibitors, methods and compositions therefor
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
US20230285523A1 (en) * 2021-12-20 2023-09-14 Tiakis Biotech Ag Use of elafin in the treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
AU5192790A (en) * 1989-02-23 1990-09-26 Center For Blood Research, The Human elastase inhibitor
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff

Also Published As

Publication number Publication date
NO902444D0 (no) 1990-06-01
AU5680890A (en) 1990-12-13
DE69024104D1 (de) 1996-01-25
ATE131493T1 (de) 1995-12-15
CA2018592C (en) 2002-08-27
PT94326B (pt) 1997-01-31
US5464822A (en) 1995-11-07
GR3018401T3 (en) 1996-03-31
US6893843B2 (en) 2005-05-17
NO177716B (no) 1995-07-31
US20020187535A1 (en) 2002-12-12
AU636148B2 (en) 1993-04-22
US6245739B1 (en) 2001-06-12
DE69024104T2 (de) 1996-06-13
NZ233974A (en) 1993-05-26
ES2080800T3 (es) 1996-02-16
NO902444L (no) 1990-12-10
PT94326A (pt) 1991-02-08
IE902006L (en) 1990-12-09
DK0402068T3 (da) 1996-04-22
JPH03148299A (ja) 1991-06-25
FI106471B (fi) 2001-02-15
US20060068480A1 (en) 2006-03-30
JP2989853B2 (ja) 1999-12-13
IL94602A0 (en) 1991-04-15
FI902880A0 (fi) 1990-06-08
CA2018592A1 (en) 1990-12-09
EP0402068B1 (en) 1995-12-13
IE70520B1 (en) 1996-12-11
EP0402068A1 (en) 1990-12-12
NO177716C (no) 1995-11-08

Similar Documents

Publication Publication Date Title
US20060068480A1 (en) Polypeptides and polypeptide analogues
Zanetti et al. The cDNA of the neutrophil antibiotic Bac5 predicts a pro-sequence homologous to a cysteine proteinase inhibitor that is common to other neutrophil antibiotics.
KR100243989B1 (ko) 사람 쿠니즈형 프로테아제 저해인자
JP2810743B2 (ja) アプロチニン同族体およびその製造方法
JP3345420B2 (ja) 新規のヒトクニツ型プロテアーゼインヒビター及びその変異体
JPH08505280A (ja) インターロイキン１βプロテアーゼおよびインターロイキン１βプロテアーゼ阻害剤
HU218104B (hu) Humán, Kunitz-típusú proteázgátló változatai
HUT70292A (en) Human kunitz-type protease inhibitor variants
JPH0866194A (ja) ヒト腫瘍壊死因子ミューテインをコードする遺伝子
JP2916228B2 (ja) 遺伝子操作した組み換えアプロチニン変異型、均質に処理されたアプロチニン変異型の微生物調製の方法およびその治療学的使用
IE903245A1 (en) Proteins having anticoagulant activity
Bourbonnais et al. Production of full-length human pre-elafin, an elastase specific inhibitor, from yeast requires the absence of a functional yapsin 1 (Yps1p) endoprotease
AU8172787A (en) Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same
JP2769083B2 (ja) エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
Dalbøge et al. Cloning and expression of an interleukin-1β precursor and its conversion to interleukin-1β
AUERSWALD et al. Synthesis, cloning and expression of recombinant aprotinin
EP0264118B1 (en) Novel method for preparing proteins
CA1341318C (en) Dna clones of human placental plasminogen activator inhibitor
US5231010A (en) Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
WO1995003333A2 (en) Tryptase inhibitor
JP2623807B2 (ja) セリンプロテアーゼおよびセリンプロテアーゼ遺伝子
JPH0841098A (ja) 新規阻害剤
JPH1156365A (ja) 変異体ケクスタチン

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
KB Patent renewed